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Background: KRAS mutations negatively affect outcome after treatment with cetuximab in metastatic colorectal
cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients respond to cetuximab it is possible that other
mutations, constitutively activating the EGFR pathway, are present in the non-responding KRAS WT patients. We
retrospectively analyzed objective tumor response rate, (ORR) progression-free (PFS) and overall survival (OS) with
respect to the mutational status of KRAS, BRAF, PIK3CA and PTEN expression in mCRC patients treated with a
cetuximab-based regimen.
Methods: 67 mCRC patients were enrolled onto the study. DNA was extracted from paraffin-embedded sections
derived from primary or metastatic lesions. Exon 2 of KRAS and exon 15 of BRAF were analyzed by direct
sequencing, PIK3CA was evaluated by pyrosequencing and PTEN expression by immunohistochemistry.
Results: BRAF and PIK3CA mutations were independently associated with worse PFS (p= 0.006 and p= 0.028,
respectively) and OS (p= 0.008 and p= 0.029, respectively). No differences in clinical outcome were found between
patients who were positive or negative for PTEN expression. Conversely, patients negative for KRAS, BRAF and PIK3CA
mutations were characterized by significantly better ORR, PFS and OS than patients with at least one of these
mutations.
Conclusions: BRAF and PIK3CA mutations would seem to be independent predictors of anti-EGFR therapy
effectiveness and could be taken into consideration during treatment decision making.
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Colorectal cancer (CRC) is the third most common form
of cancer and the second leading cause of cancer-related
death. Although early diagnosis may allow radical surgery
to be performed and result in a complete cure, about 25%
of patients present with metastatic disease at diagnosis and
about 40-50% of resected patients will develop distant
metastases and die [1]. There is evidence that the use of
polychemotherapy with fluoropyrimidines, oxaliplatin* Correspondence: a.passardi@irst.emr.it
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reproduction in any medium, provided the orand irinotecan can significantly improve overall survival
(OS) in patients with metastatic CRC (mCRC) with re-
spect to those who do not receive all three drugs. The use
of bevacizumab in association with chemotherapy has
also been shown to prolong OS [2].
Current treatment options for mCRC include cetuxi-
mab (CTX), a chimeric IgG1 monoclonal antibody which
binds to the epidermal growth factor receptor (EGFR),
leading to inhibition of its downstream signaling. How-
ever, objective response rates (ORRs) in unselected
mCRC populations are only around 8–12% for CTX
when used in monotherapy [2-5]. As a number of retro-
spective studies have shown that somatic mutations of
KRAS can negatively affect the efficacy of CTX [6-8], the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with wild type (WT) KRAS. Despite this, relatively
few patients benefit from CTX: ORRs are around 13% (vs
about 1% in KRAS mutated) for monotherapy [9] and
about 60% (vs 35% in KRAS mutated) when combined
with chemotherapy [10,11]. These findings clearly suggest
that other resistance mediators exist in non-responding
WT patients. The predictive value of additional mutations
and deregulations of signaling pathways downstream of
EGFR such as BRAF, PIK3CA, or PTEN is currently under
intensive investigation.
BRAF plays a crucial role in the KRAS pathway and a
key mutation (V600E) in exon 15 has been described in
colon cancer [12,13]. A number of retrospective and pre-
clinical studies have recently suggested that BRAF muta-
tions are mutually exclusive with those of KRAS and may
indicate resistance to anti-EGFR therapy in mCRC
patients as well as in cellular models of CRC [14,15].
The PIK3CA gene is another downstream effector of
KRAS and its pathway is normally inhibited by PTEN.
The role of the PIK3CA/PTEN pathway in resistance to
EGFR inhibitors has been investigated extensively in
KRAS WT patients and cellular models of CRC, with
conflicting results [16-22].
We retrospectively analyzed the relation between ORR,
progression-free survival (PFS) and OS and the muta-
tional status of KRAS, BRAF, PIK3CA and PTEN expres-
sion in mCRC patients treated with a CTX-based
regimen, with the aim of clarifying the relative contribu-
tion of these molecular alterations to clinical outcome.
Methods
Patient population and treatment regimens
We retrospectively analyzed 67 evaluable patients with
EGFR-positive mCRC, consecutively treated with a CTX-
based regimen at Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori in Meldola, Italy, from March
2004 to October 2010. Inclusion criteria were pathological
diagnosis of stage IV colorectal adenocarcinoma, age> 18
years, Eastern Cooperative Oncology Group performance
status< 3. Patients treated before June 2009 were selected
for CTX on the basis of EGFR expression alone as KRAS
mutational status evaluation had still not been made
mandatory by the Italian Regulatory Authority. All patients
treated after June 2009 had tumors negative for KRAS
mutations.
Data on patient characteristics, treatment and outcome
were collected. Treatment was continued until disease
progression or toxicity occurred, as per standard criteria.
Clinical response was assessed every 8 weeks with
complete radiological examination (CT or MRI scan)
and was evaluated a posteriori according to Response
Evaluation Criteria in Solid Tumors (RECIST) guidelines.
Objective tumor responses were classified into partialresponse (PR), stable disease (SD) or progressive disease
(PD). Patients with SD or PD were defined as non-
responders. The ORR was defined as the fraction of
patients with complete or partial response confirmed at≥
4 weeks after the initial response. Toxicity was evaluated
according to National Cancer Institute Common Ter-
minology Criteria for Adverse Events v 3.0 guidelines for
each patient receiving at least one dose of study
treatment.
The study was approved by the local Ethical Commit-
tee in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki. All patients gave their
written informed consent.
Molecular analyses
Formalin-fixed paraffin-embedded (FFPE) tumor blocks
were reviewed for quality and tumor content. DNA was
extracted from 5-μM FFPE sections of primary or meta-
static lesions containing at least 50% of tumor cells. Exon
2 of KRAS and exon 15 of BRAF genes were amplified by
PCR using the following primers: forward 5’-GGT GAG
TTT GTA TTA AAA GGT ACT GG-3’ and reverse 5’
GGT CCT GCA CCA GTA ATA TGC-3’ for KRAS, and
forward 5’ TCA TAA TGC TTG CTC TGA TAG GA-3’
and reverse 5’- GGC CAA AAATTTAAT CAG TGG A-3’
for BRAF. PCR products were purified using MiniElute
PCR purification kit (Qiagen, Hilden, Germany) and then
submitted to sequencing using BigDye Terminator 3.1
Reaction Cycle Sequencing kit (Applied Biosystems, Foster
City, CA). Sequence reactions were purified using
DyeEx 2.0 Spin kit (Qiagen) and separated by capillary
electrophoresis with laser-induced fluorescence detec-
tion (3100 Genetic Analyzer, Applied Biosystems).
PIK3CA status was analyzed by pyrosequencing using
anti-EGFR MoAb response (PIK3CA status) (Diatech,
Jesi, Ancona, Italy), according to the manufacturer’s
instructions. Reactions were run on a PyroMark Q96 ID
(Qiagen). PTEN protein expression was analyzed by
immunohistochemistry using a Dako monoclonal anti-
body diluted 1:100. Samples with ≥ 5% immunopositive
neoplastic cells of any intensity in cytoplasm and/or nu-
cleus were considered as PTEN-positive.
Statistical analyses
A two-sided Fisher's exact test was used to evaluate the
association between mutations and ORR. PFS was calcu-
lated from the first day of treatment to the date of first
observation of disease progression or last follow-up or
death in the absence of progressive disease. OS was cal-
culated from the first day of treatment to the date of
death of any cause, or last follow-up. PFS, OS and their
95% confidence intervals (95% CI) were estimated using
the Kaplan-Meier life-table method [23] and survival
curves were compared by the logrank test [24].
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of response to therapy and the 95% CI for mutational
status in univariate analysis. Hazard ratios (HR) and their
95% CI were estimated according to Cox multiple regres-
sion model to evaluate the independent predictive role of
mutational status of KRAS, BRAF, PIK3CA and PTEN
expression in PFS and OS [25]. Statistical significance
was assumed for p< 0.05. Statistical analyses were car-
ried out with SAS Statistical software (version 9.1, SAS
Institute, Cary, NC).KRAS
Figure 1 Distribution of different molecular alterations in
individual tumors of the 67 patients. KRAS and BRAF mutations
occurred in a mutually exclusive manner in all but one patient, while
an overlapping pattern was observed among the other gene
alterations.Results
Molecular alterations
Among the 39 patients treated with CTX-based treat-
ment before June 2009 we detected 14 (36%) KRAS
mutations, whereas all 28 patients treated after June
2009 had WT KRAS. In the overall series, 10 (71%)
KRAS mutations occurred in codon 12, of which 4 were
G12V, 3 G12S, 2 G12D and 1 G12A alterations. In 4
(29%) cases mutations occurred in codon 13 and were all
G13D alterations. BRAF mutations were detected in 12
(17.9%) patients and all were V600E alterations. Muta-
tions in the PIK3CA gene were detected in 9 (13.4%)
patients involving exon 9 (4 E545K, 2 E542K, 1 E545G)
in 7 cases and exon 20 (both H1047R) in 2 cases. Loss of
PTEN expression was observed in 40 (59.7%) cases.
KRAS and BRAF mutations occurred in a mutually ex-
clusive manner in all but one patient, while an overlap-
ping pattern was observed among the other gene
alterations. We observed only one mutation in 28 cases,
two overlapping mutations in different combinations in
16 cases and three overlapping alterations in 5 cases.
The most frequent overlapping alterations were BRAF/
PTEN (9 cases), PIK3CA/PTEN (7 cases) and KRAS/
PIK3CA/PTEN (3 cases) (Figure 1).Clinical variables
Clinical characteristics of patients are shown in Table 1.
Our cohort included heavily pretreated patients, more
than 75% of whom had received at least 2 lines of chemo-
therapy for metastatic disease, including irinotecan, oxali-
platin and fluoropyrimidines, and in 38.8% of cases,
bevacizumab. The vast majority of patients (89.5%) were
treated with irinotecan-based chemotherapy plus CTX.
Overall there were 17 responders (ORR 25.4%) and 50 non
responders (74.6% of whom 28.3% SD and 46.3% PD).
Analysis of clinical variables showed that only cutaneous
toxicity (2–3 vs 0) and ECOG PS (1–2 vs 0) were asso-
ciated with significantly better median PFS (p=0.014 and
0.0007, respectively). Other clinical variables including
gender, site of primary tumor (colon, rectum), age and
number of previous cancer treatments for advanced dis-
ease were not predictors of clinical outcome.Molecular alterations and clinical outcomes: Univariate
analyses
The role of each molecular alteration is shown in Table 2.
We found a better, albeit not statistically significant, ORR
in patients with WT tumors with respect to those with
KRAS, BRAF, or PIK3CA mutations, while no differences
were found in PTEN-positive compared to PTEN-negative
patients. At a median follow-up of 28 months, 61 cases of
progressive disease and 57 deaths had been registered. Me-
dian PFS and OS were significantly better in patients with
wild type BRAF and PIK3CA. Only a trend towards a bet-
ter median PFS was observed in patients with wild type
KRAS or with high PTEN expression.
Molecular alterations and clinical outcomes: Multivariate
analyses
Multivariate analysis was performed on all 4 molecular
alterations and was adjusted for PS, cutaneous toxicity,
and number of previous chemotherapy lines. No correl-
ation was found between mutation status and lack of ob-
jective response. The analysis did, however, confirm, that
wild type BRAF and PIK3CA were significantly and inde-
pendently associated with better PFS [HR= 2.65 (95% CI
1.33-5.29), p= 0.006 and HR= 2.46 (95% CI 1.10-5.52),
p= 0.028, respectively], with KRAS mutations also exert-
ing a detrimental borderline effect [HR= 1.86 (95% CI
0.99-3.47), p= 0.052]. Conversely, PTEN expression was
not correlated with PFS. With regard to OS, BRAF and
PIK3CA mutations were once again associated with
decreased survival [HR= 2.47 (95% CI 1.26-4.85),
p= 0.008 and HR= 2.51 (95% CI 1.10-5.72), p= 0.029, re-
spectively], whereas KRAS and PTEN alterations did not
independently affect clinical outcome (Table 3).
In accordance with the new patient selection criteria
for CTX, we analyzed the effect of BRAF and PIK3CA
Table 1 Baseline patient characteristics
n (%)
No. of patients 67
Median age, yrs (range) 61 (34–79)
Gender (male/female)
Male 39 (58.2%)
Female 28 (41.8%)
Performance Status
0 37 (55.2%)
1-2 30 (44.8%)
Primary tumor site
Colon 54 (80.6%)
Rectum 13 (19.4%)
Treatment regimen
CTX+ irinotecan/folfiri 60 (89.5%)
CTX + FOLFOX4 6 (9.0%)
CTX alone 1 (1.5%)
Previous chemotherapy
Irinotecan-based 62 (92.5%)
Fluoropyrimidine-based 67 (100%)
Oxaliplatin-based 54 (80.6%)
Bevacizumab-based 26 (38.8%)
No. of previous cancer treatments for
advanced disease
One 15 (22.4%)
Two 28 (41.8%)
Three 15 (22.4%)
More than three 9 (13.4%)
Cutaneous toxicity
0 19 (32.8%)
1 19 (32.8%)
2–3 20 (34.5%)
Unknown 9
Table 2 Biomolecular alterations and ORR, PFS and OS:
univariate analysis
n ORR % Median PFS
(months)
(95% CI)
p Median OS
(months)
(95% CI)
p
Overall 67 4.3 (2.9-5.5) - 9.2 (7.3-12.0) -
KRAS
WT 53 30.2 5.2 (3.4-6.7) 8.7 (6.9-14.6)
Mut 14 7.1 2.7 (2.2-3.9) 0.070 9.4 (6.0-12.0) 0.114
BRAF
WT 55 29.1 5.1 (3.2-6.7) 9.6 (8.3-13.9)
Mut 12 8.3 2.8 (1.4-3.9) 0.005 5.8 (2.1-8.4) 0.008
PIK3CA
WT 58 27.6 5.1 (3.4-6.2) 9.9 (8.3-13.7)
Mut 9 11.1 2.3 (2.1-3.3) 0.031 6.6 (4.4-7.3) 0.013
PTEN
<5% 40 22.5 3.3 (2.3-5.2) 8.3 (6.0-12.4)
≥5% 27 29.6 6.2 (4.0-8.7) 0.073 11.0 (8.0-14.6) 0.647
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type KRAS tumors. At multivariate analysis, BRAF muta-
tion was confirmed as a predictor of worse PFS [HR=3.15
(95% CI 1.51-6.59), p=0.002] and OS [HR=2.87 (95% CI
1.37-6.00), p=0.005] and PIK3CA mutations were corre-
lated with a shorter, albeit not statistically significant, PFS,
whereas no correlation was observed with respect to OS.
Finally, PTEN expression was not found to affect either
PFS or OS.
Number of tumor molecular alterations and clinical
outcome
The contribution of the number of mutations in deter-
mining the clinical outcome of patients was examined.
In particular, we considered the combination of KRAS,BRAF and PIK3CA mutations, excluding PTEN expres-
sion because of its low impact as an independent pre-
dictive marker. Our results showed that 38 (56.7%)
patients did not have any alterations, 23 (34.3%) had one
mutation and 6 (9.0%) had 2 mutations.
Objective response rates were 36.8% in ‘triple wild
type’ patients and 13.0% in those with one mutation,
while no responses were observed in patients with 2
mutations. The odds ratio of response was 0.20 (95% CI
0.05-0.77) (p= 0.020) in patients with at least one muta-
tion compared to those with no mutations. Similarly,
survival analysis showed that patients with at least one
mutation had worse PFS and OS with respect to those
with none. In particular, median PFS (95% CI) was 5.5
(5.1-8.7), 2.9 (2.3-3.6) and 2.2 months (1.1-3.3) for
patients harboring no alterations, one or two alterations,
respectively, p< 0.001 (Figure 2). Median OS (95% CI)
was 13.9 (8.3-17.6), 7.3 (5.8-9.5) and 6.4 months (3.7-9.6)
for patients harboring no alterations, one or two altera-
tions, respectively, p= 0.001 (Figure 3).
Discussion
The clinical impact of monoclonal antibodies targeting
EGFR in patients with mCRC has been clearly estab-
lished. In particular CTX, alone or in combination with
conventional chemotherapy, has been shown to improve
the outcome of patients treated in first-, second- and
third-line settings. KRAS mutational status is currently a
validated predictive biomarker used to select mCRC
patients for EGFR-targeted drugs, such as CTX and
panitumumab. However, response rates to either drug
are less than 20% in wild-type KRAS patients. Although
recent reports have indicated that BRAF, PIK3CA or
Table 3 Biomolecular alterations and ORR, PFS and OS: multivariate analysis
PFS
HR (95% CI)
p OS
HR (95% CI)
p
KRAS (mutated vs wild type) 1.86 (0.99-3.47) 0.052 1.56 (0.83-2.96) 0.170
BRAF (mutated vs wild type) 2.65 (1.33-5.29) 0.006 2.47 (1.26-4.85) 0.008
PIK3CA (mutated vs wild type) 2.46 (1.10-5.52) 0.028 2.51 (1.10-5.72) 0.029
PTEN (<5% vs ≥5%) 1.47 (0.85-2.54) 0.169 0.89 (0.50-1.57) 0.686
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of resistance to these drugs, results are still conflicting
[14,15,19-22,26,27]. Our case series included patients with
KRAS wt and KRAS mutated tumors treated with CTX be-
fore June 2009, and others selected with KRAS wt tumors
treated after June 2009. We observed a better, albeit not
statistically significant, ORR, OS and PFS in patients with
KRAS wt tumors with respect to those with KRASmutated
tumors. This lack of statistical significance may be a result
of the limited number of mutated cases due to the selec-
tion of wt patients after June 2009. It is also possible that a
complex relationship exists between anti-EGFR response
and KRAS status due to the synergistic effects of mutant
and wild type KRAS proteins [28].
Data were recently published on a subgroup analysis of
patients treated with chemotherapy and CTX (trial
NCIC CTG CO.17), showing that those with tumors har-
boring KRAS G13D mutations (14.5% of the KRAS0.00
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Figure 2 PFS on the basis of the number of tumor molecular alteratio
harboring no (5.5 months), one (2.9 months) or two (2.2 months) alterationmutated group) had better PFS and OS compared to
patients with other KRAS mutations. No significant differ-
ences in PFS and OS were noted when patients with KRAS
G13D mutations were compared with those with wild type
KRAS tumors [29]. In our experience 4 patients with KRAS
G13D mutation did not respond. No correlations can be
made with other types of mutations because of the low
number of such mutations found. However, of the four
patients with the G12V mutation, which is considered the
most aggressive KRAS alteration in colorectal cancer
[30,31], only one showed a partial response.
Significantly worse OS and PFS were observed in
BRAF or PIK3CA mutated patients, suggesting that these
two alterations may play an important role in determin-
ing anti-EGFR resistance. In particular, we found a high
incidence of BRAF mutations (17.9%), possibly due to
the high prevalence of wild type KRAS tumors which
more frequently harbor alterations of the BRAF gene. It6 9 12
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Figure 3 OS on the basis of the number of tumor molecular alterations. A significant difference (p< 0.001) was observed among patients
harboring no (13.9 months), one (7.3 months) or two (6.4 months) alterations.
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BRAF is associated with resistance to treatment with
anti-EGFR antibodies [14,15]. However, other studies
have reported that BRAF mutations appear to be prog-
nostic rather than predictive as mCRC patients not re-
ceiving CTX also have markedly reduced survival when
tumors harbor a BRAF mutation [32-34]. All these stud-
ies suggest that a BRAF mutation precludes benefit from
any type of treatment. Similarly, our multivariate analysis
on KRAS wt patients confirmed BRAF mutation as a sig-
nificant predictor of worse PFS and OS following CTX-
containing treatment.
Conflicting results have been obtained for PIK3CA
mutations and CTX response [6,21,33,35,36]. In our
study exon 9 and 20 mutations of the gene were asso-
ciated with significantly worse PFS and OS, suggesting
that the constitutive kinase activity of the mutated pro-
tein may overcome the inhibition signal from CTX.
Moreover, in the subgroup of KRAS wild type patients,
PIK3CA status was significantly associated with a better
PFS and with a better, albeit not statistically significant,
OS.
We did not obtain significant results on PTEN alterations,
in accordance with some studies [21,27] but in contrast to
others in which a correlation was observed between the lack
of PTEN expression and response to CTX [19,37]. Thediscordance between the different immunohistochemical
studies could be due to a number of factors, e.g. a lack of
standardization of the reagents and protocols used; the ab-
sence of a single cut off value; or the subjective interpret-
ation of the operators who evaluated the samples from a
morphological point of view. As the best cut off to define
PTEN positivity has not been clearly established, we used a
value of 5%.Conclusions
Our study shows that BRAF and PIK3CA mutations are
independently associated with worse ORR, PFS and OS,
and that patients with wild type KRAS, BRAF and
PIK3CA status have a significantly better outcome with
respect to patients with at least one alteration. These
results suggest that BRAF and PIK3CA could also be
taken into consideration in the decision making for
CTX-based treatment. Having said that, the number of
patients in the present work is too small to reach any
definitive conclusions, and larger prospective studies are
now needed to validate our findings. Moreover, it would
be opportune to confirm the results in a series of
patients not treated with CTX in order to exclude the
possibility that BRAF and PIK3CA mutations have a
prognostic rather than predictive value.
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